In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
20 authors.
Samuel D WhedonDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0002-3745-5645 Kwangwoon LeeDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0002-2021-5186 Zhipeng A WangDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0002-5693-7359 Emily ZahnDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Congcong LuFrontiers Science Center for Cell Responses, College of Life Sciences, Nankai University, Tianjin, 300071, China.
Maheeshi Yapa-AbeywardanaDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0002-9773-2587 Louise FairallLeicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1 7RH, United Kingdom.ORCID 0000-0001-9456-3047 Eunju NamDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0003-0801-9331 Sarah Dubois-CoyneDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0001-5143-099X Pablo De IoannesDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, United States.ORCID 0000-0003-1944-3912 Xinlei ShengThe Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, United States.ORCID 0000-0002-5067-8915 Adelina AndreiDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0009-0009-1687-2173 Emily LundbergDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.
Jennifer JiangDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.ORCID 0000-0001-5186-5838 Karim-Jean ArmacheDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, United States.
Yingming ZhaoThe Ben May Department for Cancer Research, University of Chicago, Chicago, IL 60637, United States.ORCID 0000-0003-1928-2151 John W R SchwabeLeicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Leicester, LE1 7RH, United Kingdom.ORCID 0000-0003-2865-4383 Benjamin A GarciaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Philip A ColeDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States.
Funding
Shared Resources Core 2: Quantitative Proteomics CoreP01CA196539 · NCI · ROCKEFELLER UNIVERSITY · PI YOUNG, MICHAEL WARREN · 2015 to 2024
$17.6MStructural and functional analysis of gene silencingR01GM115882 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ARMACHE, KARIM JEAN · 2015 to 2023
$3.4MHistone lactylation pathway in hair cycle: deacylases and their protein targetsR01AR078555 · NIAMS · UNIVERSITY OF CHICAGO · PI LIN, HENING, ZHAO, YINGMING · 2021 to 2025
$3.3MLactate production by tumor associated macrophages promotes tumorigenesisR01CA251677 · NCI · UNIVERSITY OF CHICAGO · PI BECKER, LEV, ZHAO, YINGMING · 2021 to 2025
$2.8MMolecular basis for aberrant de novo DNA methylation in cancerR01CA266978 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Karim Jean Armache, Chao Lu · 2022 to 2026
$2.6MQuantitative mass spectrometry for comprehending epigenetic mechanisms in a new underlying neurological developmental disorderR01HD106051 · NICHD · WASHINGTON UNIVERSITY · PI Benjamin A Garcia · 2022 to 2026
$2.6MChemical Approaches to Understanding Reversible Lysine ModificationsR35GM149229 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI PHILIP A COLE · 2023 to 2026
$1.9MEpigenetic mechanisms of regulation of histone lysine methyltransferases involved in leukemiaR01GM144547 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Karim Jean Armache · 2023 to 2026
$1.8MNCI NIH HHS P01 CA196539NCI NIH HHS R01 CA251677NCI NIH HHS R01 CA266978NIAMS NIH HHS R01 AR078555NICHD NIH HHS R01 HD106051NIGMS NIH HHS R01 GM115882NIGMS NIH HHS R01 GM144547NIGMS NIH HHS R35 GM149229Wellcome Trust
6 · The paper itselfAbstract
Reversible modification of the histone H3 N-terminal tail is critical in regulating chromatin structure, gene expression, and cell states, while its dysregulation contributes to disease pathogenesis. Understanding the crosstalk between H3 tail modifications in nucleosomes constitutes a central challenge in epigenetics. Here we describe an engineered sortase transpeptidase, cW11, that displays highly favorable properties for introducing scarless H3 tails onto nucleosomes. This approach significantly accelerates the production of both symmetrically and asymmetrically modified nucleosomes. We demonstrate the utility of asymmetrically modified nucleosomes produced in this way in dissecting the impact of multiple modifications on eraser enzyme processing and molecular recognition by a reader protein. Moreover, we show that cW11 sortase is very effective at cutting and tagging histone H3 tails from endogenous histones, facilitating multiplex "cut-and-paste" middle down proteomics with tandem mass tags. This cut-and- paste proteomics approach permits the quantitative analysis of histone H3 modification crosstalk after treatment with different histone deacetylase inhibitors. We propose that these chemoenzymatic tail isolation and modification strategies made possible with cW11 sortase will broadly power epigenetics discovery and therapeutic development.
Identifiers
PMID39372790
PMCPMC11451751
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390